BBNX 9-DAY DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

Beta Bionics (NASDAQ: BBNX) is facing a securities class action lawsuit for allegedly concealing critical FDA compliance issues and device safety warnings. The complaint alleges the company failed to disclose over 18,000 unreported customer complaints regarding the iLet Bionic Pancreas, including algorithm failures and severe hypoglycemia events. Stock declined 37% on January 8, 2026 after missing patient start expectations, and further dropped following an FDA Warning Letter on February 24, 2026. The lead plaintiff deadline is November 3, 2026.